NO20084857L - HPV-16-basert papillomavirus vaksine - Google Patents

HPV-16-basert papillomavirus vaksine

Info

Publication number
NO20084857L
NO20084857L NO20084857A NO20084857A NO20084857L NO 20084857 L NO20084857 L NO 20084857L NO 20084857 A NO20084857 A NO 20084857A NO 20084857 A NO20084857 A NO 20084857A NO 20084857 L NO20084857 L NO 20084857L
Authority
NO
Norway
Prior art keywords
hpv
preventing
treating
papillomavirus vaccine
papillomavirus
Prior art date
Application number
NO20084857A
Other languages
English (en)
Norwegian (no)
Inventor
Ronald Rooke
Stephane Paul
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of NO20084857L publication Critical patent/NO20084857L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO20084857A 2006-04-21 2008-11-18 HPV-16-basert papillomavirus vaksine NO20084857L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06360014 2006-04-21
PCT/EP2007/003368 WO2007121895A2 (en) 2006-04-21 2007-04-17 Hpv-16-based papillomavirus vaccine

Publications (1)

Publication Number Publication Date
NO20084857L true NO20084857L (no) 2008-11-18

Family

ID=38362856

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084857A NO20084857L (no) 2006-04-21 2008-11-18 HPV-16-basert papillomavirus vaksine

Country Status (13)

Country Link
US (1) US20100061957A1 (enExample)
EP (1) EP2013230A2 (enExample)
JP (1) JP2009534332A (enExample)
KR (1) KR20090005011A (enExample)
CN (1) CN101426811A (enExample)
AU (1) AU2007241406A1 (enExample)
BR (1) BRPI0710238A2 (enExample)
CA (1) CA2649392A1 (enExample)
IL (1) IL193661A0 (enExample)
MX (1) MX2008013488A (enExample)
NO (1) NO20084857L (enExample)
RU (1) RU2008145712A (enExample)
WO (1) WO2007121895A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8926961B2 (en) * 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
US9789129B2 (en) 2008-04-17 2017-10-17 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
EP2239330A1 (en) 2009-04-07 2010-10-13 Institut Pasteur Neuron generation, regeneration and protection
JP5964298B2 (ja) * 2010-07-15 2016-08-03 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ ヒトパピローマウイルスｅ７抗原組成物およびその使用
CN102343103B (zh) * 2011-07-26 2016-04-27 马丁 人乳头状瘤病毒16型三肽疫苗的筛选和验证及持续表达hpv16 e5, e6, e7的肿瘤动物模型的构建
EP2601968A1 (en) * 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum HPV derived polynucleic acids for therapy
EP3632464A1 (en) 2012-06-15 2020-04-08 PDS Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
EP4091630A1 (en) 2012-09-21 2022-11-23 PDS Biotechnology Corporation Vaccines comprising r-dotap
US9000736B2 (en) 2013-05-03 2015-04-07 Cooper Technologies Company Power factor correction algorithm for arbitrary input waveform
US9190901B2 (en) 2013-05-03 2015-11-17 Cooper Technologies Company Bridgeless boost power factor correction circuit for constant current input
US9214855B2 (en) 2013-05-03 2015-12-15 Cooper Technologies Company Active power factor correction circuit for a constant current power converter
US9548794B2 (en) 2013-05-03 2017-01-17 Cooper Technologies Company Power factor correction for constant current input with power line communication
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
AU2017272356A1 (en) * 2016-06-03 2018-12-20 Etubics Corporation Compositions and methods for the treatment of human papillomavirus (HPV)-associated diseases
KR20190073416A (ko) 2016-10-05 2019-06-26 피디에스 바이오테크놀러지 코퍼레이션 신규한 hpv16 hla-비제한적 t-세포 백신, 조성물 및 이의 사용 방법
CA3121247A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
WO2002077012A2 (en) * 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
CA2502696A1 (en) * 2002-10-21 2004-05-06 Mgi Pharma Biologics, Inc. Compositions and methods for treating human papillomavirus-mediated disease

Also Published As

Publication number Publication date
BRPI0710238A2 (pt) 2011-08-09
MX2008013488A (es) 2008-10-30
US20100061957A1 (en) 2010-03-11
KR20090005011A (ko) 2009-01-12
AU2007241406A1 (en) 2007-11-01
WO2007121895A2 (en) 2007-11-01
RU2008145712A (ru) 2010-05-27
WO2007121895A3 (en) 2008-03-20
IL193661A0 (en) 2011-08-01
CA2649392A1 (en) 2007-11-01
JP2009534332A (ja) 2009-09-24
CN101426811A (zh) 2009-05-06
EP2013230A2 (en) 2009-01-14

Similar Documents

Publication Publication Date Title
NO20084857L (no) HPV-16-basert papillomavirus vaksine
WO2007121894A3 (en) Hpv-18-based papillomavirus vaccine
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
MX2009011865A (es) Tratamiento de lesiones viralmente inducidas.
MY150604A (en) 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities
BRPI0511078A (pt) compostos de pirimidinona cìclicos, composição compreendendo os mesmos, método de inibição e uso
ATE503769T1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
MX345700B (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
MY152710A (en) Oral compositions containing extracts of garcinia mangostana l. and related methods
DE602006010564D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
ATE503770T1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
NO20084396L (no) Kombinasjonsterapi
EA201000329A1 (ru) Циклические депсипептиды
IL176522A0 (en) Universal amplification of fragmented rna
UA96279C2 (ru) Изолированное антитело или его фрагмент, способное к связыванию с человеческим nogo
DE60330257D1 (de) Zusammensetzung zur impfung
NO20070980L (no) Selekterte kondenserte heterocykler og anvendelser derav
BRPI0706871A2 (pt) uso de um extrato de sambucus nigra l., método de tratamento de uma infecção viral de influenza e método de inibição da infecção viral de influenza
NO20080650L (no) Forbindelser omfattende DMXAA for behandling av kreft
WO2009107864A3 (en) An orally disintegrating tablet of cilostazol
CL2009000791A1 (es) Compuestos derivados de labirintopeptina; procedimiento para prepararlos que comprende fermentar la cepa actinomadura namibiensis (dsm 6313); uso de los compuestos para tratar infecciones bacterianas, infecciones viricas y/o dolor; composicion farmaceutica que los comprenden; dna que codifica la preprolabirintopeptina a2.
WO2009120022A3 (ko) 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물
WO2012089742A3 (en) IDENTIFICATION OF A NOVEL HUMAN POLYOMAVIRUS (IPPyV) AND APPLICATIONS
WO2010033619A3 (en) Systems, methods, and compositions for detection of human papilloma virus in biological samples

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application